In:
Cancer, Wiley, Vol. 106, No. 8 ( 2006-04-15), p. 1838-1845
Abstract:
The combination of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine was just as active and tolerable as other regimens that have been tested in recent clinical trials for patients with Ewing sarcoma (ES) and extraosseous ES/primitive neuroectodermal tumors. Dose intensification was correlated with better disease control and a high percentage of necrosis in high‐risk patients with these tumors.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2006
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1